SG11202102659RA - Anti-human cd45rc antibodies and uses thereof - Google Patents
Anti-human cd45rc antibodies and uses thereofInfo
- Publication number
- SG11202102659RA SG11202102659RA SG11202102659RA SG11202102659RA SG11202102659RA SG 11202102659R A SG11202102659R A SG 11202102659RA SG 11202102659R A SG11202102659R A SG 11202102659RA SG 11202102659R A SG11202102659R A SG 11202102659RA SG 11202102659R A SG11202102659R A SG 11202102659RA
- Authority
- SG
- Singapore
- Prior art keywords
- human cd45rc
- antibodies
- cd45rc antibodies
- human
- cd45rc
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306230.6A EP3626265A1 (en) | 2018-09-21 | 2018-09-21 | Anti-human cd45rc antibodies and uses thereof |
| PCT/EP2019/075374 WO2020058495A1 (en) | 2018-09-21 | 2019-09-20 | Anti-human cd45rc antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202102659RA true SG11202102659RA (en) | 2021-04-29 |
Family
ID=63713787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202102659RA SG11202102659RA (en) | 2018-09-21 | 2019-09-20 | Anti-human cd45rc antibodies and uses thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220033500A1 (en) |
| EP (2) | EP3626265A1 (en) |
| JP (1) | JP2022502024A (en) |
| KR (1) | KR20210070303A (en) |
| CN (1) | CN113164595A (en) |
| AU (1) | AU2019343746A1 (en) |
| BR (1) | BR112021005276A2 (en) |
| CA (1) | CA3113562A1 (en) |
| IL (1) | IL281608A (en) |
| MX (1) | MX2021003281A (en) |
| SG (1) | SG11202102659RA (en) |
| WO (1) | WO2020058495A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL296546A (en) * | 2020-03-20 | 2022-11-01 | Inst Nat Sante Rech Med | Chimeric antigen receptor specific for human cd45rc and uses thereof |
| CA3231944A1 (en) | 2021-09-16 | 2023-03-23 | Carole GUILLONNEAU | Anti-human cd45rc binding domains and uses thereof |
| CA3240875A1 (en) | 2021-12-23 | 2023-06-29 | Stefanie Urlinger | Discernible cell surface protein variants of cd45 for use in cell therapy |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| AU633698B2 (en) | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| DK1136556T3 (en) | 1991-11-25 | 2005-10-03 | Enzon Inc | Process for the preparation of multivalent antigen-binding proteins |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| SE9400088D0 (en) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| ES2571230T3 (en) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedure to control the activity of an immunofunctional molecule |
| FR2807767B1 (en) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | MONOCLONAL ANTIBODIES ANTI-D |
| ES2405944T3 (en) | 2000-11-30 | 2013-06-04 | Medarex, Inc. | Nucleic acids encoding reorganized human immunoglobulin sequences from transgenic transchromosomal mice zadas |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
| WO2004010957A2 (en) | 2002-07-31 | 2004-02-05 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| BR122018071808B8 (en) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugate |
| EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| WO2005084390A2 (en) | 2004-03-02 | 2005-09-15 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
| ES2715776T3 (en) | 2004-11-12 | 2019-06-06 | Seattle Genetics Inc | Auristatins that have an aminobenzoic acid unit at the N-terminus |
| EP1898529A1 (en) | 2005-06-28 | 2008-03-12 | Pioneer Corporation | Broadcast receiving apparatus, interference detecting apparatus and interference detecting method |
| HUE057936T2 (en) | 2005-07-18 | 2022-06-28 | Seagen Inc | Beta-glucuronide drug linker conjugates |
| EP1929073A4 (en) | 2005-09-27 | 2010-03-10 | Amunix Inc | Proteinaceous pharmaceuticals and uses thereof |
| JP5328019B2 (en) | 2005-10-21 | 2013-10-30 | レヴォ バイオロジクス インコーポレイテッド | Antibody with enhanced antibody-dependent cytotoxic activity, its preparation and use |
| CN101784664B (en) | 2007-06-01 | 2013-04-10 | Omt公司 | Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies |
| US20120258496A1 (en) | 2010-09-27 | 2012-10-11 | Boehringer Ingelheim International Gmbh | Production of low fucose antibodies in h4-ii-e rat cells |
| FR3003171B1 (en) | 2013-03-15 | 2015-04-10 | Lab Francais Du Fractionnement | NOVEL MEDICAMENTS COMPRISING AN ENHANCED ANTIBODY COMPOSITION IN MAJORITY LOAD ENFORCEMENT |
| ES2726645T3 (en) | 2014-08-01 | 2019-10-08 | Inst Nat Sante Rech Med | An anti-CD45RC antibody to use as a medicine |
| GB201601073D0 (en) * | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| EP3498293A1 (en) | 2017-12-15 | 2019-06-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Treatment of monogenic diseases with an anti-cd45rc antibody |
-
2018
- 2018-09-21 EP EP18306230.6A patent/EP3626265A1/en not_active Withdrawn
-
2019
- 2019-09-20 US US17/277,511 patent/US20220033500A1/en active Pending
- 2019-09-20 BR BR112021005276-3A patent/BR112021005276A2/en unknown
- 2019-09-20 AU AU2019343746A patent/AU2019343746A1/en active Pending
- 2019-09-20 MX MX2021003281A patent/MX2021003281A/en unknown
- 2019-09-20 JP JP2021516406A patent/JP2022502024A/en active Pending
- 2019-09-20 KR KR1020217011256A patent/KR20210070303A/en active Search and Examination
- 2019-09-20 WO PCT/EP2019/075374 patent/WO2020058495A1/en unknown
- 2019-09-20 CA CA3113562A patent/CA3113562A1/en active Pending
- 2019-09-20 CN CN201980076451.4A patent/CN113164595A/en active Pending
- 2019-09-20 SG SG11202102659RA patent/SG11202102659RA/en unknown
- 2019-09-20 EP EP19778452.3A patent/EP3852802A1/en active Pending
-
2021
- 2021-03-17 IL IL281608A patent/IL281608A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021003281A (en) | 2021-08-11 |
| KR20210070303A (en) | 2021-06-14 |
| JP2022502024A (en) | 2022-01-11 |
| BR112021005276A2 (en) | 2021-07-13 |
| EP3626265A1 (en) | 2020-03-25 |
| WO2020058495A1 (en) | 2020-03-26 |
| US20220033500A1 (en) | 2022-02-03 |
| CN113164595A (en) | 2021-07-23 |
| AU2019343746A1 (en) | 2021-04-15 |
| EP3852802A1 (en) | 2021-07-28 |
| IL281608A (en) | 2021-05-31 |
| CA3113562A1 (en) | 2020-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202004494B (en) | Anti-tmprss2 antibodies and antigen-binding fragments | |
| IL276950A (en) | Anti-cd73 antibodies and uses thereof | |
| IL282968A (en) | Anti-nkg2a antibodies and uses thereof | |
| IL275734B (en) | Anti-pd-l1 antibodies and uses thereof | |
| ZA201701920B (en) | Anti-human il-17 monoclonal antibodies and use thereof | |
| IL275826A (en) | Anti-mct1 antibodies and uses thereof | |
| IL281272A (en) | Humanized anti-c5 antibodies and uses thereof | |
| SG11202009772PA (en) | Anti-dll3 antibodies and uses thereof | |
| IL281297A (en) | Anti-npr1 antibodies and uses thereof | |
| IL281608A (en) | Anti-human cd45rc antibodies and uses thereof | |
| IL277330A (en) | Anti-il-27 antibodies and uses thereof | |
| SG11202103095RA (en) | Anti-human vsig4 antibodies and uses thereof | |
| SG11202009625WA (en) | Anti-trem-1 antibodies and uses thereof | |
| IL280321A (en) | Anti-cxcr2 antibodies and uses thereof | |
| IL283875A (en) | Anti-il-27 antibodies and uses thereof | |
| IL281202A (en) | Anti-tnfrsf9 antibodies and uses thereof | |
| IL277075A (en) | Anti-phf-tau antibodies and uses thereof | |
| IL276548A (en) | Bcma-binding antibodies and uses thereof | |
| SG11202012680TA (en) | Anti-l1cam antibodies and uses thereof | |
| IL283926A (en) | Anti-alpha-synuclein antibodies and uses thereof | |
| IL283890A (en) | Anti-periostin antibodies and uses thereof | |
| IL277296A (en) | Anti-pfrh5 antibodies and antigen-binding fragments thereof | |
| ZA202004784B (en) | Humanized and de-immunized antibodies | |
| IL279790A (en) | Anti-l1cam antibodies and uses thereof | |
| GB201918103D0 (en) | Epitopes and antibodies |